Shipping ADCs with Confidence: Eliminating the Risks That Keep Program Leaders Up at Night
Antibody-drug conjugates (ADCs) represent some of the most promising, and most complex, therapies in...
read Details
Understanding + Applying Annex 1: New EU GMP
Understanding + Applying Annex 1: New EU GMP
The global regulatory experts at Modality Solutions provide a detailed, tactical approach for meeting the new requirements for container closure integrity (CCI) of sterile pharmaceutical products detailed in the revised Annex 1 EU GMP.
Download the slide deck created by industry experts, Andrew Larrigan and Carson Dickey to understand how the changes to EU Annex 1 will impact your cold chain strategy for container closure integrity.
Receive this webinar to your email
You may also like
Misalignment Is a Silent Killer—And the FDA Is Looking for Cracks
FDA Uncertainty: Why First-Cycle Approval Is Now a Matter of Survival Leadership shake-ups, budget...
read Details
In This New Regulatory Landscape, You’re Either Ready—or at Risk
FDA Uncertainty: Why First-Cycle Approval Is Now a Matter of Survival Leadership shake-ups, budget...
read Details